Genentech, Inc.
NEWS
The U.S. Food and Drug Administration (FDA) approved a prefilled syringe for self-injection of an allergic diseases treatment developed by Novartis and Genentech, a Roche company.
There was a fair amount of clinical trial news last week. Here’s a look.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
The U.S. FDA approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.
JOBS
IN THE PRESS